Sernova is a clinical-stage biotechnology company that is developing therapeutic cell technologies for chronic diseases, including insulin-dependent diabetes, thyroid disease, and hemophilia A. The Company is currently focused on developing a ‘functional cure’ for insulin-dependent diabetes with the Cell Pouch System™, a novel implantable and scalable cell therapy platform transplanted initially with human donor islets but ultimately using an iPSC islet like cluster technology exclusively licensed from Evotec SE. The company is currently progressing a Phase 1/2 clinical trial evaluating the Cell Pouch System in patients with T1D with impaired hypoglycemia awareness. Of six patients in the first cohort of the trial, five are now insulin-independent, with the first patient at almost four years without the need for insulin injections and a normalized HbA1c. Enrollment in a second cohort of 7 patients is complete, with data to come in early 2024.